News
Stay informed of LENZ therapeutics latest developments.
LENZ Therapeutics LNZ101 and LNZ100 Phase 3 Timeline
LENZ Provides Phase 3 Timing Guidance
LENZ Therapeutics provided Phase 3 timing and formulation guidance for LNZ100 and LNZ101. LNZ100 is a 1.75% Aceclidine based eye drop while LNZ101 is a 1.75% Aceclidine based eye drop with Brimonidine. Both use LENZ's proprietary preservative free vehicle matrix to maximize comfort, efficacy and bioavailability.